Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > well just maybe

<< Previous

Bullboard Posts

Next >>

Comment by 2b7f6fabon Oct 25, 2023 3:16pm

193 Views

Post# 35700723

RE:RE:RE:RE:RE:RE:RE:well just maybe

Data leaks to Merck are good. No, great! Merck only has about 4 years patent life left. Merck needs Ruvidar now to get a dozen or so clinical trials up, running and completed before 2028.

Then comes Merck’s Keytruda. Top executives have long been pressed on what Merck has in store for life after the PD-1 king loses its market exclusivity in 2028. With Merck's recent Organon spinoff, the company is even more reliant on Keytruda, but it also has $9 billion in new cash to scout for deals.

<< Previous

Bullboard Posts

Next >>

This junior mining stock offers billions in market exposure